Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Capvaxive by Quarter
Capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — International sales ($M) ($M)
Merck Capvaxive: $45M in Q2 2026. That is the highest of the 10 quarters on record here.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-07) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — International sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 45 | – | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 23 | +2,200.0% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 21 | – | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q3 2025 | Sep 30, 2025 | 7 | – | Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 0 | – | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 1 | – | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2024 | Dec 31, 2024 | 0 | – | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q3 2024 | Sep 30, 2024 | 0 | – | Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 0 | – | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 0 | – | Form 10-Q (filed 2025-05-02) ↗ |
Cite this data
StockData. (2026). Merck Capvaxive ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-capvaxive-intl
See every metric in the Merck KPI table. Data updated Oct 26, 2026.